The traditional use of medicinal plants for treatment of infectious diseases by an indigenous Mbyá-Guarani tribe from South Brazil was assessed by evaluating the antibiotic and antibiofilm activities against relevant bacterial pathogens. Aqueous extracts from 10 medicinal plants were prepared according to indigenous Mbyá-Guarani traditional uses. To evaluate antibiotic (OD600) and antibiofilm (crystal violet method) activities, Pseudomonas aeruginosa ATCC 27853, Staphylococcus epidermidis ATCC 35984 and seven multi-drug resistant Klebsiella pneumoniae carbapenemase (KPC)-producing bacterial clinical isolates were challenged with the extracts. Furthermore, the susceptibility profile of KPC-producing bacteria and the ability of these isolates to form biofilm were evaluated. The plants Campomanesia xanthocarpa, Maytenus ilicifolia, Bidens pilosa and Verbena sp. showed the best activity against bacterial growth and biofilm formation. The majority of KPC-producing isolates, which showed strong ability to form biofilm and a multidrug resistance profile, was inhibited by more than 50% by some extracts. The Enterobacter cloacae (KPC 05) clinical isolate was the only one resistant to all extracts. This study confirms the importance of indigenous traditional medicinal knowledge and describes for the first time the ability of these plants to inhibit biofilm formation and/or bacterial growth of multi-drug resistant KPC-producing isolates.
Since the introduction of antibiotics, bacteria have developed sophisticated resistance strategies. This resistance can be acquired in several ways, including the ability to form biofilm and the production of enzymes capable of inactivating antibiotics. Bacteria in the biofilm mode of growth are between 10 to 1,000 times less susceptible to antimicrobial agents and host immune response, contributing to the chronic character of infections [1] . In addition, the global spread of carbapenemase-producing Enterobacteriaceae represents a real threat to vulnerable hospitalized patients [2,3a] . The carbapenemases most frequently found in this bacterial family are the Klebsiella pneumoniae carbapenemase (KPC) [3b] . These β-lactamases are able to hydrolyze all β-lactamic antibiotics, including carbapenems. In addition, they also can confer resistance to other drugs, such as aminoglycosides and quinolones, promoting a scenario in which less therapeutic options are available for treatment [3c] . KPC-producing bacteria have spread worldwide, and currently these microorganisms represent a serious public health problem, since they have been held responsible for several disease outbreaks in different countries [3b-4] . Consequently, investigating compounds with novel mechanisms of action is required to combat the growing health threat from pathogenic bacteria that have developed resistance to current drug classes.
Finding healing powers of plants is an ancient practice, and doubtless the native Indian populations are the guardians of biodiversity information and knowledge about how to extract natural resources from native plants [5a-7a] . It is unquestionable that a deep understanding of medicinally useful plants, based on their traditional use, is kept by indigenous healers, which have for a long time used ecologically sustainable holistic medicinal drugs [7b,8] . Therefore, indigenous knowledge, transmitted from generation to generation over centuries, becomes important in the context of developing novel pharmaceuticals [6b,9] .
Indigenous people that remain in their traditional territory and who therefore hold considerable ethnopharmacological knowledge are recognized as a key resource for bioprospection of new drugs, new drug leads, and new chemical entities [7b,5b,10] . Few groups have such vast knowledge of the chemical properties of plants as the South American indigenous populations [7c]. In fact, medicinal plants have formed the basis of sophisticated traditional medicine systems, as developed by the Mbyá-Guarani ethnic group along centuries [9,11a] . Today, the Guarani is one of the largest indigenous groups in Brazil (approximately 34,000 individuals), formed by three major tribes Kayová, Nhandeva and Mbyá (Fundação Nacional do Índio) [12] . In addition, ethnopharmacological surveys provide the rationale for selection and scientific investigation of medicinal plants, since some of these indigenous remedies have successfully been used by significant numbers of people throughout recent history [3a] . Due to the emergence of multiple drug resistant isolates, scientists have devoted considerable efforts to study plants, since they contain a wide variety of secondary metabolites with antimicrobial action [5a] .
The purpose of the present study was to investigate the antibiotic and antibiofilm potential of plants traditionally used by Mbyá-Guarani, an indigenous tribe from South Brazil against KPCproducing isolates and biofilm-forming bacteria. In the present study, the antibiotic and antibiofilm activities from 10 medicinal plants were assessed. The choice of plant species was based on ethnopharmacological information used by Mbyá-Guarani natives, from the Tekoá Anhetenguá tribe, Porto Alegre, RS, Brazil, to treat infectious diseases (Table 1) . Twenty Mbyá-Guarani families live in this village, named Tekoá Anhetenguá (in English, True Village) and that covers an area of 10 hectares [24] . The older women of the tribe collect plants, traditionally used to treat infectious diseases such as influenza, cough, urination pain, toothache, and diarrhea, among others. KPC-producing isolates are an emergent group of bacteria presenting high resistance to various drugs and that causes infections with high morbidity and mortality rates [3e]. The KPC isolates were previously evaluated against the most important classes of antimicrobials (aminoglycoside, carbapenem, cephalosporin and quinolone), demonstrating a multidrug resistance profile (Table 2) . Furthermore, the majority of these isolates showed a strong capacity to form biofilm (Table 2) . This characteristic increases the pathogenicity of isolates, since biofilms constitute a protected mode of growth and their inherent resistance to antimicrobial agents is usually the cause of many chronic bacterial infections [25, 26] .
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Pseudomonas aeruginosa is an opportunistic pathogen that causes disease in immunocompromised individuals. S. epidermidis is the leading etiologic agent in infections associated with medical implants. P. aeruginosa and Staphylococcus epidermidis are difficult to eradicate, and cause persistent infections mainly due to their ability to form biofilms [25] .
In this context, the present study is the first report describing the use of these medicinal plants against biofilm formation. The effect of aqueous extracts, at 4.0 and 0.4 mg/mL, on biofilm formation and bacterial growth of all isolates is summarized in Table 3 .
Additionally, the antibiotic activity against P. aeruginosa and KPCproducing isolates has likewise not been previously described.
The aqueous extract of leaves from Campomanesia xanthocarpa showed the greatest effect against the bacterial strains. At a concentration of 4.0 mg/mL, the extract reduced biofilm formation by S. epidermidis (15 1850 Natural Product Communications Vol. 10 (11) 2015
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174, KPC 177, and KPC 182. We observed an intriguing case when the effect of the extract from M. ilicifolia was analyzed against KPC 10. This extract completely inhibited the growth of this bacterium, but biofilm formation was not affected (92.6%). There are two reasonable explanations for these phenomena: (i) the isolate possesses an extremely fast ability to form biofilm in the first hours of the assay, but after 24 h the extract kills the bacteria, leading to staining of dead adhered cells on the polystyrene plate (as assessed by the crystal violet method). The rationale of this method, widely used for the quantification of biofilm, is based on measurement of the total biomass of biofilm with no distinction between live and dead cells; (ii) the action of antibiotics may cause stress to the bacterial cells, stimulating them towards biofilm formation as a selfprotection strategy against the hostile environment [27] . The M. ilicifolia leaves infusion is commonly used against gastric disorders in Brazil [16b] . The triterpenes present in the leaves of this plant have been reported as promising alternatives with anti-inflammatory and antiulcerogenic activity [16a] . Interestingly, the indigenous Mbyá-Guarani from Tekoá Anhetenguá resort to infusion of stems to treat urination pain and menstrual cramps, as opposed to the traditional use of leaves.
The diverse profiles of resistance of clinical isolates and the rise of multidrug-resistant pathogens place emphasis on the significant challenge hospitals currently face, reinforcing the importance of studies to find molecules and the urgent need for novel treatments.
Considering the high percentage of medicinal plants active against drug-resistant clinical strains and traditionally used by the Mbyá natives, it is possible to hypothesize that traditional medicine worldwide can provide a number of active compounds. Interestingly, the active extracts presented no specificity for Grampositive or Gram-negative strains, which may be considered an advantage in the research and development of new therapies. Moreover, this tallies with the highly diverse traditional uses by the Mbyá-Guarani people. These results unveil the importance of conservation of cultural aspects in these native communities, and represent a relevant basis for funding strategies to preserve forests in Indian areas. This study highlighted the efficacy of antibiotic and antibiofilm activities of medicinal plants used to treat infectious diseases and, more importantly, the activity against multi-drug resistant bacterial strains.
Experimental
Plant material: The plants were collected from the indigenous tribe Mbyá-Guarani living in Lomba do Pinheiro, Porto Alegre, RS, Brazil (30°06′47.62″ S and 51°07′37.85″ W), in March 2011. Voucher specimens were deposited at the herbarium of the Universidade Federal do Rio Grande do Sul (ICN) ( Table 1 ). The project was approved by the Chieftain, by the Ethical Committee of the Universidade Federal do Rio Grande do Sul, under number 21723 and by the regional office of the National Indian Foundation (FUNAI) [12] .
Preparation of plant extracts:
The fresh plant extracts were prepared by decoction with distilled water at 60°C for 60 min, the same method used in folk medicine as practiced by the Mbyá-Guarani population. Aqueous extracts were freeze-dried and a 10 mg/mL stock solution was prepared, filtered through a 0.2 µm pore membrane and stored at −20°C until use.
Bacterial strains: Pseudomonas aeruginosa ATCC 27853 (Gramnegative) and Staphylococcus epidermidis ATCC 35984 (Grampositive) were used as biofilm-forming models. We also evaluated seven KPC-producing multidrug resistant clinical isolates recovered from a hospital located in Porto Alegre city ( Table 2 ). The identification of these isolates was initially performed by conventional biochemical methodology, and was subsequently confirmed using the automated system VITEK 2 (bioMérieux, UK). The susceptibility profile was evaluated according to standard methods (CLSI, 2011). The characterization of KPC-producers included phenotypic (Modified Hodge Test and combined-disks test with boronic acid) and genotypic assays. The polymerase chain reaction (PCR) to detect the KPC gene was performed using previously described primers and reaction conditions [28] .
Bacterial suspension: Bacterial strains were grown in Mueller Hinton agar (Oxoid Ltd., England) for 24 h at 37°C. A bacterial suspension was prepared in 0.9% NaCl, corresponding to 1 on the McFarland scale (3x10 8 CFU/mL) and used in all assays.
Biofilm formation and antibiofilm assay: Biofilm formation capacity of the KPC-producing isolates was assessed according to Antunes et al., with minor modifications [29] . A volume of 80 µL of the bacterial suspension was added to each well of a sterile 96-well polystyrene flat-bottom microtiter plate (Costar 3599, Corning, NY, USA). Next, wells were filled with 80 µL of water and 40 µL of trypticase soy broth (TSB) medium (Oxoid Ltd., England). The plates were then incubated for 24 h at 37ºC. To remove nonadherent cells, the wells were rinsed 3 times with sterile saline. The attached bacteria were heat-fixed at 60°C for 1 h. Crystal violet (0.4%) was used to stain the bacteria for 15 min. The biofilm was eluted with 99.5% DMSO (Sigma-Aldrich Co., USA) and absorbance was measured at 570 nm (Spectramax M2e Multimode Microplate Reader, Molecular Devices, USA). In accordance with the criteria defined by Stepanović et al., the isolates were classified as non-biofilm producer, weak biofilm producer, moderate biofilm producer and strong biofilm producer [30, 31] .
The antibiofilm assay was performed as described by Trentin et al. [31] . A bacterial suspension was added to each well, followed by the aqueous extract (0.4 mg/mL or 4.0 mg/mL) and TSB. The plates were incubated for 24 h at 37°C. The following steps (washing, fixation, and staining) were performed as described above in the biofilm formation assay. The control of biofilm formation (untreated sample) consisted of 80 µL of the bacterial suspension, 40 µL of TSB and 80 µL of water. Values higher than 100% represent a stimulation of biofilm formation, in comparison with the control.
Antibiotic assay: Bacterial growth was evaluated based on the difference between initial (t = 0) and final (t = 24 h) absorbance at 600 nm in the microtiter plate. In the untreated sample (control), the extracts were replaced by 80 µL of water (100% of bacterial growth). Values higher than 100% represent a stimulation of bacterial growth, in comparison with the control. Rifampicin 8 µg/mL (Sigma-Aldrich Co., USA) was used as a control for the inhibition of bacterial growth of S. epidermidis. Gentamicin 20 µg/mL was used as control for P. aeruginosa and KPC-producing isolates.
